DE2905033A1 - Wasserloeslicher fester medikamententraeger - Google Patents
Wasserloeslicher fester medikamententraegerInfo
- Publication number
- DE2905033A1 DE2905033A1 DE19792905033 DE2905033A DE2905033A1 DE 2905033 A1 DE2905033 A1 DE 2905033A1 DE 19792905033 DE19792905033 DE 19792905033 DE 2905033 A DE2905033 A DE 2905033A DE 2905033 A1 DE2905033 A1 DE 2905033A1
- Authority
- DE
- Germany
- Prior art keywords
- water
- agents
- esp
- polyvinyl alcohol
- medicament carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 229920002451 polyvinyl alcohol Polymers 0.000 title claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 239000004372 Polyvinyl alcohol Substances 0.000 title claims description 8
- 239000004902 Softening Agent Substances 0.000 title abstract 2
- 230000002035 prolonged effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims abstract description 16
- 230000007062 hydrolysis Effects 0.000 claims abstract description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 10
- 239000000654 additive Substances 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims description 9
- 239000004014 plasticizer Substances 0.000 claims description 2
- 229940126589 solid medicine Drugs 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 238000010438 heat treatment Methods 0.000 abstract description 4
- 229920002689 polyvinyl acetate Polymers 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- -1 moitics Substances 0.000 abstract description 2
- 239000002637 mydriatic agent Substances 0.000 abstract description 2
- 230000002911 mydriatic effect Effects 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 238000003797 solvolysis reaction Methods 0.000 abstract description 2
- 239000005526 vasoconstrictor agent Substances 0.000 abstract description 2
- 229940124428 anticataract agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000003292 diminished effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000011197 physicochemical method Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000002544 virustatic Substances 0.000 abstract 1
- 230000001790 virustatic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 13
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 6
- 239000004327 boric acid Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229960003943 hypromellose Drugs 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 239000012907 medicinal substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241001136792 Alle Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792905033 DE2905033A1 (de) | 1979-02-09 | 1979-02-09 | Wasserloeslicher fester medikamententraeger |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792905033 DE2905033A1 (de) | 1979-02-09 | 1979-02-09 | Wasserloeslicher fester medikamententraeger |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2905033A1 true DE2905033A1 (de) | 1980-08-28 |
| DE2905033C2 DE2905033C2 (enExample) | 1989-05-18 |
Family
ID=6062599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792905033 Granted DE2905033A1 (de) | 1979-02-09 | 1979-02-09 | Wasserloeslicher fester medikamententraeger |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE2905033A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0110157A1 (en) * | 1982-10-28 | 1984-06-13 | Pennwalt Corporation | Granular pesticide composition |
| WO1991001714A1 (en) * | 1989-07-27 | 1991-02-21 | Smith & Nephew Plc | Ophthalmic composition |
| CN110538166A (zh) * | 2019-08-15 | 2019-12-06 | 莆田学院 | 聚乙烯醇缓释膜、聚乙烯醇缓释微针及其制备方法 |
-
1979
- 1979-02-09 DE DE19792905033 patent/DE2905033A1/de active Granted
Non-Patent Citations (1)
| Title |
|---|
| Pharmazeutische Technologie, Sucker, Fuchs, Speiser, Stuttgart, 1978, S. 297-298, 702-705 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0110157A1 (en) * | 1982-10-28 | 1984-06-13 | Pennwalt Corporation | Granular pesticide composition |
| WO1991001714A1 (en) * | 1989-07-27 | 1991-02-21 | Smith & Nephew Plc | Ophthalmic composition |
| CN110538166A (zh) * | 2019-08-15 | 2019-12-06 | 莆田学院 | 聚乙烯醇缓释膜、聚乙烯醇缓释微针及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2905033C2 (enExample) | 1989-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69710756T2 (de) | Orale zeitversetzt schnell freisetzende formulierung sowie verfahren zu deren herstellung | |
| DE69919713T2 (de) | Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium | |
| DE3688532T2 (de) | Pharmazeutische darreichungsform mit verzoegerter abgabe. | |
| DE60019116T2 (de) | Neue omeprazole und (s)-omeprazole zusammensetzung | |
| DE3783394T2 (de) | Arzneizubereitung zur oralen anwendung. | |
| AT392901B (de) | Verfahren zur herstellung einer granulaeren form mit verzoegerter freisetzung von pharmazeutisch wirksamen substanzen | |
| DE69212710T2 (de) | Pharmazeutische Zusammensetzung mit kontrollierter Freigabe und bioadhäsiven Eigenschaften | |
| DE69022876T2 (de) | Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe. | |
| DE69521987T2 (de) | Amoxicillin zweischichttabletten | |
| DE3876724T2 (de) | Die zur freisetzung bioaktiver substanzen kontrollierende umhuellungszubereitung. | |
| DE69720778T2 (de) | ARZNEIMITTEL ZUR VERZÖGERTEN FREISETZUNG DES HMG-CoA REDUKTASE INHIBITORS FLUVASTATIN | |
| DE69003568T2 (de) | Arzneimittel mit verzögerter Freigabe. | |
| EP0934058B1 (de) | Stabile arzneiform mit benzimidazolderivaten als wirkstoff zur oralen verabreichung und verfahren zu ihrer herstellung | |
| DE3872739T2 (de) | Arzneimittel mit langsamer freisetzung. | |
| EP0032562A1 (de) | Neue Dipyridamol-Retardformen und Verfahren zu ihrer Herstellung | |
| EP1509200B1 (de) | Filmförmige, zerfallsfähige zubereitungen zur wirkstoff-freisetzung und verfahren zu deren herstellung | |
| DE1617374A1 (de) | Verfahren zum Herstellen eines pharmazeutischen Praeparates mit verzoegerter Wirkung | |
| DE1093050B (de) | Verfahren zur Herstellung einer Penicillintablette mit verlaengerter Wirkung | |
| DE1617724A1 (de) | Verfahren zur Herstellung von Arzneimitteln mit verzoegerter Wirkung | |
| DE3612305A1 (de) | Fluessige arzneiform zur therapie der psoriasis auf basis filmbildender polymere | |
| DD292374A5 (de) | Verfahren zum herstellen von ueberzugsmaterialien zur steuerung der arzneimittelfreisetzung bei langzeitwirkenden zubereitungen | |
| EP0306699A1 (de) | Dihydropyridin-Retard-Zubereitung | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| DE602004009552T2 (de) | Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel | |
| DE102007026037A1 (de) | Gastroretentives System mit Alginat-Körper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |